Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Down 61.9% in March

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a large drop in short interest in March. As of March 15th, there was short interest totalling 23,500 shares, a drop of 61.9% from the February 28th total of 61,700 shares. Based on an average daily volume of 239,900 shares, the short-interest ratio is currently 0.1 days. Approximately 2.6% of the shares of the stock are short sold.

Revelation Biosciences Stock Performance

REVB stock opened at $2.83 on Thursday. The firm has a market cap of $2.56 million, a P/E ratio of -0.01 and a beta of 0.17. Revelation Biosciences has a 1 year low of $2.36 and a 1 year high of $60.80. The stock’s 50 day moving average price is $3.99 and its 200 day moving average price is $8.70.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.